Co-Authors
This is a "connection" page, showing publications co-authored by Jimmy Ruiz and Stefan Grant.
Connection Strength
0.264
-
McLouth LE, Nightingale CL, Levine BJ, Burris JL, McDougall JA, Lycan TW, Gabbard J, Ruiz J, Farris M, Blackstock AW, Grant SC, Petty WJ, Weaver KE. Unmet Care Needs and Financial Hardship in Patients With Metastatic Non-Small-Cell Lung Cancer on Immunotherapy or Chemoimmunotherapy in Clinical Practice. JCO Oncol Pract. 2021 Feb 04; OP2000723.
Score: 0.048
-
Liu L, Ahmed T, Petty WJ, Grant S, Ruiz J, Lycan TW, Topaloglu U, Chou PC, Miller LD, Hawkins GA, Alexander-Miller MA, O'Neill SS, Powell BL, D'Agostino RB, Munden RF, Pasche B, Zhang W. SMARCA4 mutations in KRAS-mutant lung adenocarcinoma: a multi-cohort analysis. Mol Oncol. 2021 02; 15(2):462-472.
Score: 0.047
-
Ahmed T, Lycan T, Dothard A, Ehrlichman P, Ruiz J, Farris M, Topaloglu U, Levine B, Grant S, Klepin HD, Petty WJ. Performance Status and Age as Predictors of Immunotherapy Outcomes in Advanced Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2020 07; 21(4):e286-e293.
Score: 0.044
-
Steffen McLouth LE, Lycan TW, Levine BJ, Gabbard J, Ruiz J, Farris M, Grant SC, Pajewski NM, Weaver KE, Petty WJ. Patient-Reported Outcomes From Patients Receiving Immunotherapy or Chemoimmunotherapy for Metastatic Non-Small-Cell Lung Cancer in Clinical Practice. Clin Lung Cancer. 2020 05; 21(3):255-263.e4.
Score: 0.044
-
Bonomi M, Ahmed T, Addo S, Kooshki M, Palmieri D, Levine BJ, Ruiz J, Grant S, Petty WJ, Triozzi PL. Circulating immune biomarkers as predictors of the response to pembrolizumab and weekly low dose carboplatin and paclitaxel in NSCLC and poor PS: An interim analysis. Oncol Lett. 2019 Jan; 17(1):1349-1356.
Score: 0.041
-
Liu L, Ruiz J, O'Neill SS, Grant SC, Petty WJ, Yang M, Chen K, Topaloglu U, Pasche B, Zhang W. Favorable outcome of patients with lung adenocarcinoma harboring POLE mutations and expressing high PD-L1. Mol Cancer. 2018 04 12; 17(1):81.
Score: 0.039